DADI Share Price Performance
Recent DADI News & Updates
No updates
Dar Al Dawa Development and Investment Co. Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.12
- Gross Margin
- 39.62%
- Net Profit Margin
- 5.07%
- Debt/Equity Ratio
- 63.3%
Dar Al Dawa Development and Investment Co. Ltd. Competitors
About DADI
- Founded
- 1975
- Employees
- 1111
- CEO
- WebsiteView website
Dar Al Dawa Development and Investment Co. Ltd., an integrated pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical and consumer healthcare products in Levant, Gulf and Yemen, the Middle East, Africa, Europe, and Asia. It operates through Medicine; and Infants’ Cereals and Milk Formula segments. The company offers products in the therapeutic areas of anti-infective, cardiovascular and diabetes, urology, respiratory, gastrointestinal, analgesic and musculoskeletal, central nervous system, gynecology, dermatology, ophthalmology, and oncology; and cereal and milk formula products for infants. It serves patients and medical communities. Dar Al Dawa Development and Investment Co. Ltd. was incorporated in 1975 and is headquartered in Amman, Jordan.
Jordanian Market Performance
- 7 Days: -1.2%
- 3 Months: 23.2%
- 1 Year: 35.4%
- Year to Date: 24.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 2.5% in the Materials sector. In contrast to the last week, the market is actually up 35% over the past year. As for the next few years, earnings are expected to grow by 7.8% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading